RSS-0343 Drug Asset Due Diligence Report 2026

This RSS-0343 Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 11 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: HOLD / OPTION

Decision memo

Preserve optionality until clinical differentiation, transaction economics, and freedom-to-operate are sufficiently de-risked.

The central underwriting question is whether RSS-0343 can convert its Small molecule drug profile and DPP-1 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	RSS-0343 (query alias: RSS-0343)
Modality / target	Small molecule drug; DPP-1; DPP-1 inhibitors
Highest global status	Phase 2
Originator	Reistone Biopharma Co. Ltd.
Active developers	Jiangsu Hengrui Pharmaceuticals Co., Ltd., Reistone Biopharma Co. Ltd.

The MCP disease footprint includes Pulmonary Disease, Chronic Obstructive, Asthma, Non-cystic fibrosis bronchiectasis. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07696091	Phase 1	Not yet recruiting	40	Primary endpoint not disclosed in English source
NCT07349524	Phase 2	Recruiting	300	Primary endpoint not disclosed in English source
NCT07289464	Phase 1	Completed	48	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Evidence gap

The Clinical Trials MCP returned no matched public result record. This is a gating diligence gap, not evidence of failure.

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

RSS-0343 addresses Pulmonary Disease, Chronic Obstructive, Asthma, Non-cystic fibrosis bronchiectasis. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 6 matched transaction record(s) under the scope “target-level comparable: DPP-1.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: DPP-1 records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2025-08-13	PANTHERx® Rare Selected by Insmed to Dispense BRINSUPRI™ (brensocatib) for the Treatment of Non-Cystic Fibrosis Bronchiectasis	Approved	Financial terms not disclosed
2025-08-13	VytlOne Announces New Partnership with Insmed	Approved	Financial terms not disclosed
2025-08-11	Fosun Pharma's Small Molecule Innovative Drug XH-S004 Achieves Overseas Licensing for a Potential Total of $645 Million	Phase 2	US$645.0M stated total

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Polymorph of benzo[c]chroman compound, preparation method therefor and use thereof”. The milestone feed surfaced a patent-application signal described as “Pharmaceutically acceptable salt of benzo[c]chroman compound and polymorphic form and use of pharmaceutically acceptable salt”. The milestone feed surfaced a patent-application signal described as “Small molecule inhibitor of cathepsin c and medicinal use thereof”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Therapeutic index and off-target toxicity
Resistance biology and biomarker-defined patient selection
Differentiation from established and emerging standards

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

HOLD / OPTION